Join to View Full Profile
Seattle Cancer Care Alliance825 Eastlake Avenue, ESeattle, WA 98109
Phone+1 206-606-2015
Dr. Tykodi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2000 - 2003
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1997 - 2000
- Washington University in St. Louis School of MedicineClass of 1997
Certifications & Licensure
- WA State Medical License 2000 - 2027
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer Start of enrollment: 2018 Aug 28
Publications & Presentations
PubMed
- Genetic and Iatrogenic Defects in Peripheral Tolerance Associated with Anti-Nephrin Antibody-Associated Minimal Change Disease.J Ashley Jefferson, Karin Chen, Sangeeta Hingorani, A Bilal Malik, Scott S Tykodi
Glomerular Diseases. 2025-01-09 - 1 citationsBelzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.Toni K Choueiri, Jaime R Merchan, Robert Figlin, David F McDermott, Edward Arrowsmith
The Lancet. Oncology. 2025-01-01 - Belzutifan for the treatment of renal cell carcinoma.Xiancheng Wu, David Lazris, Risa Wong, Scott S Tykodi
Therapeutic Advances in Medical Oncology. 2025-01-01
Press Mentions
- ASCO GU 2021: Nivolumab plus Ipilimumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma (nccRCC): Safety and Efficacy from CheckMate 920February 13th, 2021
- Vaccinia Virus and Immune Checkpoint Inhibitors: A Viable Combination in Advanced RCC?May 27th, 2020
- ASCO Annual Meeting to Highlight Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA)May 21st, 2020
- Join now to see all
Grant Support
- Targeting Novel T Cell Antigens On Renal Cell CarcinomaNational Cancer Institute2006–2010
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: